Skip to main content
Contact Us
Subscribe
E-Edition
52°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Entertainment
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Mirum Pharmaceuticals, Inc.
< Previous
1
2
Next >
Mirum Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older
March 14, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 10, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
March 08, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call on March 8, 2023
March 01, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
February 14, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference
February 09, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates
January 09, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
January 03, 2023
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Appoints Lon Cardon to Board of Directors
December 19, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older
December 13, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 09, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Provides Development Program Updates
November 29, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
November 18, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD
November 07, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022
November 01, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum’s LIVMARLI Data Featured in Two Late-Breaker Presentations at The Liver Meeting of the American Association for the Study of Liver Diseases
October 31, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC)
October 24, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals’ LIVMARLI Data Highlighting Quality of Life and Sleep Improvements in Patients with Alagille Syndrome Published in Journal of Pediatrics
October 18, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older
October 14, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Presents Long-Term LIVMARLI® (maralixibat) Data and New Alagille Syndrome Caregiver Burden Analysis at NASPGHAN 2022 Annual Meeting
October 12, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Present LIVMARLI® (maralixibat) Analyses and Host a Scientific Symposium at NASPGHAN 2022 Annual Meeting
October 05, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
August 30, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
August 12, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 10, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
August 09, 2022
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MIRM
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.